

# Corrigendum: PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study

Paul Little,<sup>1\*</sup> FD Richard Hobbs,<sup>2</sup> Michael Moore,<sup>1</sup> David Mant,<sup>3</sup> Ian Williamson,<sup>1</sup> Clodna McNulty,<sup>4</sup> Gemma Lasseter,<sup>4</sup> MY Edith Cheng,<sup>1</sup> Geraldine Leydon,<sup>1</sup> Lisa McDermott,<sup>1</sup> David Turner,<sup>1</sup> Rafael Pinedo-Villanueva,<sup>1</sup> James Raftery,<sup>1</sup> Paul Glasziou<sup>3</sup> and Mark Mullee<sup>1</sup> on behalf of the PRISM investigators

<sup>1</sup>Primary Care and Population Sciences Unit, University of Southampton, Southampton, UK

<sup>2</sup>Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK

<sup>3</sup>Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

<sup>4</sup>Public Health England, Primary Care Unit, Microbiology Laboratory, Gloucestershire Royal Hospital, Gloucester, UK

\*Corresponding author

Corrigendum issued October 2018

Corrigendum DOI: 10.3310/hta18060-c201810

Original DOI: 10.3310/hta18060

This report should be referenced as follows:

Little P, Hobbs FDR, Moore M, Mant D, Williamson I, McNulty C, *et al.* Corrigendum: PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study. *Health Technol Assess* 2014;**18**(6). Corrigendum to *Health Technol Assess* 2014;**18**(6):103–104.

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

## Corrigendum notice

### **PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study**

Paul Little, FD Richard Hobbs, Michael Moore, David Mant, Ian Williamson, Clodna McNulty, Gemma Lassetter, MY Edith Cheng, Geraldine Leydon, Lisa McDermott, David Turner, Rafael Pinedo-Villanueva, James Raftery, Paul Glasziou and Mark Mullee on behalf of the PRISM investigators

This paper<sup>1</sup> is corrected as follows:

Page 37: The text in *Chapter 4, Results, Main findings, Complications* has been replaced with the following text [these data do not alter the economic modelling (which was based on the correct data), nor the inferences from the trial that the FeverPAIN score is the optimal management approach]:

There were very few complications in any trial groups: during the first trial phase there were two cases of otitis media and one case of cellulitis in the clinical score group and one case of cellulitis in the delayed antibiotic group; during the second trial phase (when using the FeverPAIN score) there were two cases of quinsy in the delayed antibiotic group and one case of otitis media in the RADT group.

### Reference

1. Little P, Hobbs FDR, Moore M, Mant D, Williamson I, McNulty C, *et al.* PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study. *Health Technol Assess* 2014;**18**(6).